| Followers | 1440 |
| Posts | 30283 |
| Boards Moderated | 27 |
| Alias Born | 12/10/2012 |
Wednesday, July 09, 2025 11:14:10 AM
$WHWK: $230Milly in Cash on Hand
Why is this not over $50/sh yet ???
https://www.ainvest.com/news/whitehawk-therapeutics-q1-2025-results-strategic-pivot-adcs-fuels-growth-2505/
Anyways........................ loading more
GO $WHWK
Why is this not over $50/sh yet ???
https://www.ainvest.com/news/whitehawk-therapeutics-q1-2025-results-strategic-pivot-adcs-fuels-growth-2505/
Anyways........................ loading more
GO $WHWK
Recent WHWK News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:23:09 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:20:47 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:19:48 PM
- Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 • PR Newswire (US) • 04/19/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:53:19 PM
- Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series • PR Newswire (US) • 04/16/2026 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 12:03:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 12:34:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 10:46:06 PM
- Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 • PR Newswire (US) • 04/10/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/10/2026 12:38:37 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/09/2026 11:54:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 12:32:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:21:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:20:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:18:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:17:15 PM
- Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 • PR Newswire (US) • 03/17/2026 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:49:14 PM
- Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:36:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:35:11 PM
- Whitehawk Therapeutics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/26/2026 01:00:00 PM
- Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/18/2026 01:00:00 PM
- Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 • PR Newswire (US) • 01/08/2026 01:00:00 PM
